CD8A and neoplasm: To examine this, two groups of non-tumor bearing mice were vaccinated with the combination Vax/aGITR/aPD-1 therapy and one group was treated with 200 μg of aKLRG1 mAb (200 μg) at day 0, 2, 4, and 6 post-vaccination, and at day 7 after therapy initiation the expression of KLRG1 was monitored on CD8+ T cells from the blood and spleen (Supplementary Figure 3).